The study investigates circulating tumor DNA analysis in patients with large B-cell lymphomas undergoing first-line therapy, providing insights into the quantitative measurements, dynamic changes, and mutational genotypes of tumor-derived cell-free DNA during and after treatment.
The study from Meriranta et al1 in this issue of Blood details circulating tumor DNA analysis from 101 patients with large B-cell lymphomas undergoing first-line therapy on the Nordic LBC-05 trial. Using a custom capture-based sequencing approach, the authors assessed plasma cell-free DNA at time points before, during, and after immunochemotherapy. The investigators extensively analyze diverse features of tumor-derived cell-free DNA molecules, including quantitative measurements of tumor DNA, dynamic measurements during and after therapy, and mutational genotypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
